DeepPath integrates physical principles — such as atomic forces, thermodynamics, and molecular motion — into its machine learning framework. This allows the system to generate realistic, energetically valid protein movements, unlike purely data-driven models that often miss the underlying biophysical rules. Physics ensures our predictions are not just fast, but fundamentally sound.

Our “secret sauce” lies in how we combine physics and AI. Many companies use AI, and others rely on pure physics simulations, but few can merge them efficiently. DeepPath’s active learning loop is trained on minimal data yet achieves simulation-level accuracy in hours, not months — something competitors struggle to match due to either speed, accuracy, or scalability limitations.

Yes. We have validated DeepPath retrospectively against known crystal structures and prospective targets, showing its ability to recover cryptic pockets and dynamic transitions that other methods miss. We are currently expanding validation through partnerships and internal drug discovery efforts, and early results are highly promising.

DeepPath is disease-agnostic — it can be applied across oncology, inflammatory diseases, rare diseases, and beyond. Anywhere protein dynamics play a role, we can help uncover hidden binding sites and enable the design of first- or best-in-class therapeutics, opening doors to previously undruggable targets.

We work both through partnerships and internal programs. In partnerships, DeepPath integrates into a partner’s discovery pipeline, helping identify novel pockets, prioritize compounds, and design smarter drugs. Internally, we are advancing proprietary programs toward preclinical development, aiming to generate licensing-ready or IND-stage assets.